<DOC>
	<DOCNO>NCT01330108</DOCNO>
	<brief_summary>The primary objective study ass safety tolerance change patient currently bosentan ambrisentan treatment pulmonary arterial hypertension .</brief_summary>
	<brief_title>Safely Change From Bosentan Ambrisentan Pulmonary Hypertension</brief_title>
	<detailed_description>The therapy pulmonary arterial hypertension ( PAH ) revolutionize development subsequent instruction oral endothelin receptor antagonist ( ERA ) . The first approve ERA , bosentan ( Tracleer , Actelion , Inc. ) effective drug widely use throughout world therapy PAH . Newer ERA 's , purport advantage first approve drug since test subsequently approve therapy PAH USA country include ambrisentan ( Letairis , Gilead Sciences , Inc. ) . However , little data available efficacy , safety tolerability elective change oral bosentan oral ambrisentan PAH .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Patients follow routinely pulmonary vascular disease clinic University Alabama Birmingham , great equal 19 year age . 2 . World Health Organization ( WHO ) PAH Type I 3. WHO class IIV symptom ( functional class exclusion ) . 4 . On bosentan , twice day , maximum daily dose 250mg , stable dose 3 month clinical indication discontinue drug ( i.e. , increase liver function study intolerance ) . Patients may drug therapy PAH , also may oxygen therapy ( intermittent continuous ) . 1 . Known intolerance allergy ambrisentan . 2 . Prior therapy ambrisentan . 3 . Current therapy two phosphodiesterase5 inhibitor . 4 . Change approve therapy PAH ( include phosphodiesterase5 inhibitor prostanoids ) within 4 week baseline study visit . 5 . Planned addition prostanoid clinical reason within 3 month baseline study visit . 6 . Active participation another clinical study involve medical therapy PAH . 7 . Uncontrolled systemic hypertension angina pectoris 8 . Serum creatinine great 2.5 within 4 week baseline . 9 . Serum liver function study great 3 x normal within 4 week baseline study visit . 10 . In opinion investigator , change PAH therapy would present significant risk subject . 11 . In opinion investigator , participant unlikely survive 12 week study entry . 12 . In opinion investigator , participant likely undergo lung heartlung transplantation within 12 week study entry . 13 . A woman childbearing potential use acceptable form contraception . 14 . Pregnancy . 15 . In opinion investigator , participant capable willing follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>WHO Group 1</keyword>
</DOC>